nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP2E1—lung cancer	0.247	0.503	CbGaD
Dexmedetomidine—CYP1A1—lung cancer	0.244	0.497	CbGaD
Dexmedetomidine—CYP1A1—Gefitinib—lung cancer	0.0638	0.283	CbGbCtD
Dexmedetomidine—CYP1A1—Erlotinib—lung cancer	0.0377	0.168	CbGbCtD
Dexmedetomidine—CYP2D6—Gefitinib—lung cancer	0.0235	0.104	CbGbCtD
Dexmedetomidine—CYP2E1—Etoposide—lung cancer	0.0211	0.0936	CbGbCtD
Dexmedetomidine—CYP2D6—Vinorelbine—lung cancer	0.0181	0.0804	CbGbCtD
Dexmedetomidine—CYP1A2—Erlotinib—lung cancer	0.0169	0.0749	CbGbCtD
Dexmedetomidine—CYP2D6—Erlotinib—lung cancer	0.0139	0.0617	CbGbCtD
Dexmedetomidine—CYP1A2—Etoposide—lung cancer	0.0122	0.0542	CbGbCtD
Dexmedetomidine—CYP2D6—Vinblastine—lung cancer	0.0111	0.0495	CbGbCtD
Dexmedetomidine—CYP2D6—Doxorubicin—lung cancer	0.00685	0.0304	CbGbCtD
Dexmedetomidine—Haemorrhage—Docetaxel—lung cancer	0.00013	0.000652	CcSEcCtD
Dexmedetomidine—Diarrhoea—Topotecan—lung cancer	0.00013	0.00065	CcSEcCtD
Dexmedetomidine—Infection—Gemcitabine—lung cancer	0.00013	0.000649	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Irinotecan—lung cancer	0.000129	0.000648	CcSEcCtD
Dexmedetomidine—Dizziness—Vinblastine—lung cancer	0.000129	0.000647	CcSEcCtD
Dexmedetomidine—Convulsion—Cisplatin—lung cancer	0.000129	0.000646	CcSEcCtD
Dexmedetomidine—Diarrhoea—Erlotinib—lung cancer	0.000128	0.000643	CcSEcCtD
Dexmedetomidine—Abdominal pain—Vinorelbine—lung cancer	0.000128	0.000643	CcSEcCtD
Dexmedetomidine—Body temperature increased—Vinorelbine—lung cancer	0.000128	0.000643	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Docetaxel—lung cancer	0.000128	0.000643	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Gemcitabine—lung cancer	0.000128	0.000639	CcSEcCtD
Dexmedetomidine—Renal failure acute—Doxorubicin—lung cancer	0.000127	0.000637	CcSEcCtD
Dexmedetomidine—Anxiety—Cisplatin—lung cancer	0.000126	0.000633	CcSEcCtD
Dexmedetomidine—Anaemia—Etoposide—lung cancer	0.000126	0.000632	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Gemcitabine—lung cancer	0.000126	0.000631	CcSEcCtD
Dexmedetomidine—Visual impairment—Docetaxel—lung cancer	0.000126	0.000629	CcSEcCtD
Dexmedetomidine—Dizziness—Topotecan—lung cancer	0.000125	0.000628	CcSEcCtD
Dexmedetomidine—Hypotension—Irinotecan—lung cancer	0.000125	0.000626	CcSEcCtD
Dexmedetomidine—Vomiting—Vinblastine—lung cancer	0.000124	0.000622	CcSEcCtD
Dexmedetomidine—Dizziness—Erlotinib—lung cancer	0.000124	0.000622	CcSEcCtD
Dexmedetomidine—Anaemia—Paclitaxel—lung cancer	0.000124	0.000619	CcSEcCtD
Dexmedetomidine—Agitation—Paclitaxel—lung cancer	0.000123	0.000616	CcSEcCtD
Dexmedetomidine—Headache—Vinblastine—lung cancer	0.000122	0.000613	CcSEcCtD
Dexmedetomidine—Hypotension—Gemcitabine—lung cancer	0.000122	0.00061	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Docetaxel—lung cancer	0.000121	0.000605	CcSEcCtD
Dexmedetomidine—Infection—Cisplatin—lung cancer	0.000121	0.000605	CcSEcCtD
Dexmedetomidine—Vomiting—Topotecan—lung cancer	0.000121	0.000604	CcSEcCtD
Dexmedetomidine—Hypoglycaemia—Doxorubicin—lung cancer	0.00012	0.000603	CcSEcCtD
Dexmedetomidine—Rash—Topotecan—lung cancer	0.00012	0.000599	CcSEcCtD
Dexmedetomidine—Dermatitis—Topotecan—lung cancer	0.00012	0.000599	CcSEcCtD
Dexmedetomidine—Vomiting—Erlotinib—lung cancer	0.000119	0.000598	CcSEcCtD
Dexmedetomidine—Dyspnoea—Irinotecan—lung cancer	0.000119	0.000598	CcSEcCtD
Dexmedetomidine—Somnolence—Irinotecan—lung cancer	0.000119	0.000596	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Cisplatin—lung cancer	0.000119	0.000596	CcSEcCtD
Dexmedetomidine—Headache—Topotecan—lung cancer	0.000119	0.000595	CcSEcCtD
Dexmedetomidine—Tachycardia—Cisplatin—lung cancer	0.000119	0.000594	CcSEcCtD
Dexmedetomidine—Rash—Erlotinib—lung cancer	0.000118	0.000593	CcSEcCtD
Dexmedetomidine—Dermatitis—Erlotinib—lung cancer	0.000118	0.000592	CcSEcCtD
Dexmedetomidine—Convulsion—Etoposide—lung cancer	0.000118	0.000592	CcSEcCtD
Dexmedetomidine—Angiopathy—Docetaxel—lung cancer	0.000118	0.000592	CcSEcCtD
Dexmedetomidine—Hypertension—Etoposide—lung cancer	0.000118	0.00059	CcSEcCtD
Dexmedetomidine—Headache—Erlotinib—lung cancer	0.000118	0.000589	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Cisplatin—lung cancer	0.000117	0.000588	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Docetaxel—lung cancer	0.000117	0.000588	CcSEcCtD
Dexmedetomidine—Chills—Docetaxel—lung cancer	0.000117	0.000585	CcSEcCtD
Dexmedetomidine—Arrhythmia—Docetaxel—lung cancer	0.000116	0.000583	CcSEcCtD
Dexmedetomidine—Dyspnoea—Gemcitabine—lung cancer	0.000116	0.000582	CcSEcCtD
Dexmedetomidine—Nausea—Vinblastine—lung cancer	0.000116	0.000581	CcSEcCtD
Dexmedetomidine—Somnolence—Gemcitabine—lung cancer	0.000116	0.000581	CcSEcCtD
Dexmedetomidine—Convulsion—Paclitaxel—lung cancer	0.000116	0.00058	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Irinotecan—lung cancer	0.000116	0.000579	CcSEcCtD
Dexmedetomidine—Hypertension—Paclitaxel—lung cancer	0.000115	0.000578	CcSEcCtD
Dexmedetomidine—Pain—Irinotecan—lung cancer	0.000114	0.000573	CcSEcCtD
Dexmedetomidine—Constipation—Irinotecan—lung cancer	0.000114	0.000573	CcSEcCtD
Dexmedetomidine—Mental disorder—Docetaxel—lung cancer	0.000114	0.000572	CcSEcCtD
Dexmedetomidine—Hypotension—Cisplatin—lung cancer	0.000114	0.000569	CcSEcCtD
Dexmedetomidine—Anxiety—Paclitaxel—lung cancer	0.000113	0.000568	CcSEcCtD
Dexmedetomidine—Malnutrition—Docetaxel—lung cancer	0.000113	0.000568	CcSEcCtD
Dexmedetomidine—Nausea—Topotecan—lung cancer	0.000113	0.000564	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000113	0.000564	CcSEcCtD
Dexmedetomidine—Confusional state—Etoposide—lung cancer	0.000112	0.000562	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Doxorubicin—lung cancer	0.000112	0.00056	CcSEcCtD
Dexmedetomidine—Pain—Gemcitabine—lung cancer	0.000111	0.000558	CcSEcCtD
Dexmedetomidine—Constipation—Gemcitabine—lung cancer	0.000111	0.000558	CcSEcCtD
Dexmedetomidine—Nausea—Erlotinib—lung cancer	0.000111	0.000558	CcSEcCtD
Dexmedetomidine—Dry mouth—Paclitaxel—lung cancer	0.000111	0.000558	CcSEcCtD
Dexmedetomidine—Diarrhoea—Vinorelbine—lung cancer	0.000111	0.000556	CcSEcCtD
Dexmedetomidine—Infection—Etoposide—lung cancer	0.000111	0.000554	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Irinotecan—lung cancer	0.00011	0.000552	CcSEcCtD
Dexmedetomidine—Confusional state—Paclitaxel—lung cancer	0.00011	0.000551	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Irinotecan—lung cancer	0.000109	0.000548	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Etoposide—lung cancer	0.000109	0.000546	CcSEcCtD
Dexmedetomidine—Tachycardia—Etoposide—lung cancer	0.000109	0.000544	CcSEcCtD
Dexmedetomidine—Infection—Paclitaxel—lung cancer	0.000108	0.000543	CcSEcCtD
Dexmedetomidine—Dyspnoea—Cisplatin—lung cancer	0.000108	0.000543	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Etoposide—lung cancer	0.000108	0.000539	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Gemcitabine—lung cancer	0.000107	0.000538	CcSEcCtD
Dexmedetomidine—Dizziness—Vinorelbine—lung cancer	0.000107	0.000538	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Doxorubicin—lung cancer	0.000107	0.000536	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Paclitaxel—lung cancer	0.000107	0.000535	CcSEcCtD
Dexmedetomidine—Tachycardia—Paclitaxel—lung cancer	0.000107	0.000534	CcSEcCtD
Dexmedetomidine—Body temperature increased—Irinotecan—lung cancer	0.000106	0.00053	CcSEcCtD
Dexmedetomidine—Abdominal pain—Irinotecan—lung cancer	0.000106	0.00053	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Doxorubicin—lung cancer	0.000106	0.00053	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Paclitaxel—lung cancer	0.000106	0.000529	CcSEcCtD
Dexmedetomidine—Pneumonia—Methotrexate—lung cancer	0.000105	0.000527	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Cisplatin—lung cancer	0.000105	0.000526	CcSEcCtD
Dexmedetomidine—Anaemia—Docetaxel—lung cancer	0.000105	0.000525	CcSEcCtD
Dexmedetomidine—Hypotension—Etoposide—lung cancer	0.000104	0.000521	CcSEcCtD
Dexmedetomidine—Pain—Cisplatin—lung cancer	0.000104	0.000521	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Doxorubicin—lung cancer	0.000104	0.000519	CcSEcCtD
Dexmedetomidine—Vomiting—Vinorelbine—lung cancer	0.000103	0.000517	CcSEcCtD
Dexmedetomidine—Body temperature increased—Gemcitabine—lung cancer	0.000103	0.000516	CcSEcCtD
Dexmedetomidine—Rash—Vinorelbine—lung cancer	0.000102	0.000513	CcSEcCtD
Dexmedetomidine—Dermatitis—Vinorelbine—lung cancer	0.000102	0.000512	CcSEcCtD
Dexmedetomidine—Abdominal distension—Doxorubicin—lung cancer	0.000102	0.000512	CcSEcCtD
Dexmedetomidine—Hypotension—Paclitaxel—lung cancer	0.000102	0.000511	CcSEcCtD
Dexmedetomidine—Headache—Vinorelbine—lung cancer	0.000102	0.000509	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Cisplatin—lung cancer	0.0001	0.000502	CcSEcCtD
Dexmedetomidine—Dyspnoea—Etoposide—lung cancer	9.93e-05	0.000497	CcSEcCtD
Dexmedetomidine—Somnolence—Etoposide—lung cancer	9.9e-05	0.000496	CcSEcCtD
Dexmedetomidine—Convulsion—Docetaxel—lung cancer	9.82e-05	0.000492	CcSEcCtD
Dexmedetomidine—Hypertension—Docetaxel—lung cancer	9.79e-05	0.00049	CcSEcCtD
Dexmedetomidine—Dyspnoea—Paclitaxel—lung cancer	9.73e-05	0.000487	CcSEcCtD
Dexmedetomidine—Somnolence—Paclitaxel—lung cancer	9.7e-05	0.000486	CcSEcCtD
Dexmedetomidine—Nausea—Vinorelbine—lung cancer	9.64e-05	0.000483	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Etoposide—lung cancer	9.61e-05	0.000481	CcSEcCtD
Dexmedetomidine—Body temperature increased—Cisplatin—lung cancer	9.61e-05	0.000481	CcSEcCtD
Dexmedetomidine—Constipation—Etoposide—lung cancer	9.52e-05	0.000477	CcSEcCtD
Dexmedetomidine—Pain—Etoposide—lung cancer	9.52e-05	0.000477	CcSEcCtD
Dexmedetomidine—Dry mouth—Docetaxel—lung cancer	9.44e-05	0.000473	CcSEcCtD
Dexmedetomidine—Haemoglobin—Methotrexate—lung cancer	9.43e-05	0.000473	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Paclitaxel—lung cancer	9.42e-05	0.000472	CcSEcCtD
Dexmedetomidine—Haemorrhage—Methotrexate—lung cancer	9.39e-05	0.00047	CcSEcCtD
Dexmedetomidine—Constipation—Paclitaxel—lung cancer	9.34e-05	0.000468	CcSEcCtD
Dexmedetomidine—Pain—Paclitaxel—lung cancer	9.34e-05	0.000468	CcSEcCtD
Dexmedetomidine—Confusional state—Docetaxel—lung cancer	9.33e-05	0.000467	CcSEcCtD
Dexmedetomidine—Infection—Docetaxel—lung cancer	9.19e-05	0.00046	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Etoposide—lung cancer	9.17e-05	0.00046	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Doxorubicin—lung cancer	9.16e-05	0.000459	CcSEcCtD
Dexmedetomidine—Diarrhoea—Irinotecan—lung cancer	9.16e-05	0.000459	CcSEcCtD
Dexmedetomidine—Pneumonia—Doxorubicin—lung cancer	9.11e-05	0.000456	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Etoposide—lung cancer	9.1e-05	0.000456	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Docetaxel—lung cancer	9.06e-05	0.000454	CcSEcCtD
Dexmedetomidine—Visual impairment—Methotrexate—lung cancer	9.05e-05	0.000453	CcSEcCtD
Dexmedetomidine—Tachycardia—Docetaxel—lung cancer	9.03e-05	0.000452	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Paclitaxel—lung cancer	9e-05	0.000451	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Paclitaxel—lung cancer	8.93e-05	0.000447	CcSEcCtD
Dexmedetomidine—Diarrhoea—Gemcitabine—lung cancer	8.92e-05	0.000447	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Doxorubicin—lung cancer	8.88e-05	0.000445	CcSEcCtD
Dexmedetomidine—Dizziness—Irinotecan—lung cancer	8.85e-05	0.000443	CcSEcCtD
Dexmedetomidine—Abdominal pain—Etoposide—lung cancer	8.8e-05	0.000441	CcSEcCtD
Dexmedetomidine—Body temperature increased—Etoposide—lung cancer	8.8e-05	0.000441	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Doxorubicin—lung cancer	8.8e-05	0.000441	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Methotrexate—lung cancer	8.71e-05	0.000436	CcSEcCtD
Dexmedetomidine—Hypotension—Docetaxel—lung cancer	8.65e-05	0.000433	CcSEcCtD
Dexmedetomidine—Abdominal pain—Paclitaxel—lung cancer	8.63e-05	0.000432	CcSEcCtD
Dexmedetomidine—Body temperature increased—Paclitaxel—lung cancer	8.63e-05	0.000432	CcSEcCtD
Dexmedetomidine—Angiopathy—Methotrexate—lung cancer	8.52e-05	0.000427	CcSEcCtD
Dexmedetomidine—Vomiting—Irinotecan—lung cancer	8.51e-05	0.000426	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Methotrexate—lung cancer	8.46e-05	0.000424	CcSEcCtD
Dexmedetomidine—Rash—Irinotecan—lung cancer	8.44e-05	0.000423	CcSEcCtD
Dexmedetomidine—Dermatitis—Irinotecan—lung cancer	8.43e-05	0.000422	CcSEcCtD
Dexmedetomidine—Chills—Methotrexate—lung cancer	8.42e-05	0.000422	CcSEcCtD
Dexmedetomidine—Headache—Irinotecan—lung cancer	8.39e-05	0.00042	CcSEcCtD
Dexmedetomidine—Diarrhoea—Cisplatin—lung cancer	8.32e-05	0.000416	CcSEcCtD
Dexmedetomidine—Vomiting—Gemcitabine—lung cancer	8.29e-05	0.000415	CcSEcCtD
Dexmedetomidine—Bradycardia—Doxorubicin—lung cancer	8.27e-05	0.000414	CcSEcCtD
Dexmedetomidine—Dyspnoea—Docetaxel—lung cancer	8.25e-05	0.000413	CcSEcCtD
Dexmedetomidine—Somnolence—Docetaxel—lung cancer	8.23e-05	0.000412	CcSEcCtD
Dexmedetomidine—Mental disorder—Methotrexate—lung cancer	8.22e-05	0.000412	CcSEcCtD
Dexmedetomidine—Rash—Gemcitabine—lung cancer	8.22e-05	0.000412	CcSEcCtD
Dexmedetomidine—Dermatitis—Gemcitabine—lung cancer	8.21e-05	0.000411	CcSEcCtD
Dexmedetomidine—Malnutrition—Methotrexate—lung cancer	8.17e-05	0.000409	CcSEcCtD
Dexmedetomidine—Haemoglobin—Doxorubicin—lung cancer	8.17e-05	0.000409	CcSEcCtD
Dexmedetomidine—Headache—Gemcitabine—lung cancer	8.17e-05	0.000409	CcSEcCtD
Dexmedetomidine—Haemorrhage—Doxorubicin—lung cancer	8.13e-05	0.000407	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Doxorubicin—lung cancer	8.01e-05	0.000401	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Docetaxel—lung cancer	7.99e-05	0.0004	CcSEcCtD
Dexmedetomidine—Nausea—Irinotecan—lung cancer	7.95e-05	0.000398	CcSEcCtD
Dexmedetomidine—Pain—Docetaxel—lung cancer	7.91e-05	0.000396	CcSEcCtD
Dexmedetomidine—Constipation—Docetaxel—lung cancer	7.91e-05	0.000396	CcSEcCtD
Dexmedetomidine—Visual impairment—Doxorubicin—lung cancer	7.83e-05	0.000392	CcSEcCtD
Dexmedetomidine—Nausea—Gemcitabine—lung cancer	7.74e-05	0.000388	CcSEcCtD
Dexmedetomidine—Vomiting—Cisplatin—lung cancer	7.73e-05	0.000387	CcSEcCtD
Dexmedetomidine—Rash—Cisplatin—lung cancer	7.66e-05	0.000384	CcSEcCtD
Dexmedetomidine—Dermatitis—Cisplatin—lung cancer	7.66e-05	0.000383	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Docetaxel—lung cancer	7.62e-05	0.000382	CcSEcCtD
Dexmedetomidine—Diarrhoea—Etoposide—lung cancer	7.62e-05	0.000382	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Docetaxel—lung cancer	7.57e-05	0.000379	CcSEcCtD
Dexmedetomidine—Anaemia—Methotrexate—lung cancer	7.55e-05	0.000378	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Doxorubicin—lung cancer	7.54e-05	0.000378	CcSEcCtD
Dexmedetomidine—Diarrhoea—Paclitaxel—lung cancer	7.47e-05	0.000374	CcSEcCtD
Dexmedetomidine—Angiopathy—Doxorubicin—lung cancer	7.37e-05	0.000369	CcSEcCtD
Dexmedetomidine—Dizziness—Etoposide—lung cancer	7.36e-05	0.000369	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Doxorubicin—lung cancer	7.33e-05	0.000367	CcSEcCtD
Dexmedetomidine—Body temperature increased—Docetaxel—lung cancer	7.31e-05	0.000366	CcSEcCtD
Dexmedetomidine—Abdominal pain—Docetaxel—lung cancer	7.31e-05	0.000366	CcSEcCtD
Dexmedetomidine—Chills—Doxorubicin—lung cancer	7.29e-05	0.000365	CcSEcCtD
Dexmedetomidine—Arrhythmia—Doxorubicin—lung cancer	7.26e-05	0.000364	CcSEcCtD
Dexmedetomidine—Dizziness—Paclitaxel—lung cancer	7.22e-05	0.000362	CcSEcCtD
Dexmedetomidine—Nausea—Cisplatin—lung cancer	7.22e-05	0.000362	CcSEcCtD
Dexmedetomidine—Mental disorder—Doxorubicin—lung cancer	7.12e-05	0.000357	CcSEcCtD
Dexmedetomidine—Convulsion—Methotrexate—lung cancer	7.08e-05	0.000355	CcSEcCtD
Dexmedetomidine—Vomiting—Etoposide—lung cancer	7.08e-05	0.000355	CcSEcCtD
Dexmedetomidine—Malnutrition—Doxorubicin—lung cancer	7.08e-05	0.000354	CcSEcCtD
Dexmedetomidine—Rash—Etoposide—lung cancer	7.02e-05	0.000352	CcSEcCtD
Dexmedetomidine—Dermatitis—Etoposide—lung cancer	7.01e-05	0.000351	CcSEcCtD
Dexmedetomidine—Headache—Etoposide—lung cancer	6.97e-05	0.000349	CcSEcCtD
Dexmedetomidine—Vomiting—Paclitaxel—lung cancer	6.94e-05	0.000348	CcSEcCtD
Dexmedetomidine—Rash—Paclitaxel—lung cancer	6.88e-05	0.000345	CcSEcCtD
Dexmedetomidine—Dermatitis—Paclitaxel—lung cancer	6.88e-05	0.000344	CcSEcCtD
Dexmedetomidine—Headache—Paclitaxel—lung cancer	6.84e-05	0.000343	CcSEcCtD
Dexmedetomidine—Confusional state—Methotrexate—lung cancer	6.72e-05	0.000337	CcSEcCtD
Dexmedetomidine—Infection—Methotrexate—lung cancer	6.63e-05	0.000332	CcSEcCtD
Dexmedetomidine—Nausea—Etoposide—lung cancer	6.61e-05	0.000331	CcSEcCtD
Dexmedetomidine—Anaemia—Doxorubicin—lung cancer	6.54e-05	0.000328	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Methotrexate—lung cancer	6.53e-05	0.000327	CcSEcCtD
Dexmedetomidine—Agitation—Doxorubicin—lung cancer	6.5e-05	0.000326	CcSEcCtD
Dexmedetomidine—Nausea—Paclitaxel—lung cancer	6.48e-05	0.000325	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Methotrexate—lung cancer	6.45e-05	0.000323	CcSEcCtD
Dexmedetomidine—Diarrhoea—Docetaxel—lung cancer	6.33e-05	0.000317	CcSEcCtD
Dexmedetomidine—Hypotension—Methotrexate—lung cancer	6.23e-05	0.000312	CcSEcCtD
Dexmedetomidine—Convulsion—Doxorubicin—lung cancer	6.13e-05	0.000307	CcSEcCtD
Dexmedetomidine—Dizziness—Docetaxel—lung cancer	6.12e-05	0.000306	CcSEcCtD
Dexmedetomidine—Hypertension—Doxorubicin—lung cancer	6.11e-05	0.000306	CcSEcCtD
Dexmedetomidine—Anxiety—Doxorubicin—lung cancer	6e-05	0.000301	CcSEcCtD
Dexmedetomidine—Dyspnoea—Methotrexate—lung cancer	5.95e-05	0.000298	CcSEcCtD
Dexmedetomidine—Somnolence—Methotrexate—lung cancer	5.93e-05	0.000297	CcSEcCtD
Dexmedetomidine—Dry mouth—Doxorubicin—lung cancer	5.89e-05	0.000295	CcSEcCtD
Dexmedetomidine—Vomiting—Docetaxel—lung cancer	5.88e-05	0.000295	CcSEcCtD
Dexmedetomidine—Rash—Docetaxel—lung cancer	5.83e-05	0.000292	CcSEcCtD
Dexmedetomidine—Dermatitis—Docetaxel—lung cancer	5.83e-05	0.000292	CcSEcCtD
Dexmedetomidine—Confusional state—Doxorubicin—lung cancer	5.82e-05	0.000292	CcSEcCtD
Dexmedetomidine—Headache—Docetaxel—lung cancer	5.8e-05	0.00029	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Methotrexate—lung cancer	5.76e-05	0.000288	CcSEcCtD
Dexmedetomidine—Infection—Doxorubicin—lung cancer	5.74e-05	0.000287	CcSEcCtD
Dexmedetomidine—Pain—Methotrexate—lung cancer	5.7e-05	0.000286	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Doxorubicin—lung cancer	5.65e-05	0.000283	CcSEcCtD
Dexmedetomidine—Tachycardia—Doxorubicin—lung cancer	5.64e-05	0.000282	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Doxorubicin—lung cancer	5.58e-05	0.00028	CcSEcCtD
Dexmedetomidine—Nausea—Docetaxel—lung cancer	5.5e-05	0.000275	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Methotrexate—lung cancer	5.5e-05	0.000275	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Methotrexate—lung cancer	5.45e-05	0.000273	CcSEcCtD
Dexmedetomidine—Hypotension—Doxorubicin—lung cancer	5.4e-05	0.00027	CcSEcCtD
Dexmedetomidine—Abdominal pain—Methotrexate—lung cancer	5.27e-05	0.000264	CcSEcCtD
Dexmedetomidine—Body temperature increased—Methotrexate—lung cancer	5.27e-05	0.000264	CcSEcCtD
Dexmedetomidine—Dyspnoea—Doxorubicin—lung cancer	5.15e-05	0.000258	CcSEcCtD
Dexmedetomidine—Somnolence—Doxorubicin—lung cancer	5.13e-05	0.000257	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Doxorubicin—lung cancer	4.99e-05	0.00025	CcSEcCtD
Dexmedetomidine—Pain—Doxorubicin—lung cancer	4.94e-05	0.000247	CcSEcCtD
Dexmedetomidine—Constipation—Doxorubicin—lung cancer	4.94e-05	0.000247	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Doxorubicin—lung cancer	4.76e-05	0.000238	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Doxorubicin—lung cancer	4.72e-05	0.000237	CcSEcCtD
Dexmedetomidine—Abdominal pain—Doxorubicin—lung cancer	4.56e-05	0.000229	CcSEcCtD
Dexmedetomidine—Body temperature increased—Doxorubicin—lung cancer	4.56e-05	0.000229	CcSEcCtD
Dexmedetomidine—Diarrhoea—Methotrexate—lung cancer	4.56e-05	0.000229	CcSEcCtD
Dexmedetomidine—Dizziness—Methotrexate—lung cancer	4.41e-05	0.000221	CcSEcCtD
Dexmedetomidine—Vomiting—Methotrexate—lung cancer	4.24e-05	0.000212	CcSEcCtD
Dexmedetomidine—Rash—Methotrexate—lung cancer	4.2e-05	0.000211	CcSEcCtD
Dexmedetomidine—Dermatitis—Methotrexate—lung cancer	4.2e-05	0.00021	CcSEcCtD
Dexmedetomidine—Headache—Methotrexate—lung cancer	4.18e-05	0.000209	CcSEcCtD
Dexmedetomidine—Nausea—Methotrexate—lung cancer	3.96e-05	0.000198	CcSEcCtD
Dexmedetomidine—Diarrhoea—Doxorubicin—lung cancer	3.95e-05	0.000198	CcSEcCtD
Dexmedetomidine—Dizziness—Doxorubicin—lung cancer	3.82e-05	0.000191	CcSEcCtD
Dexmedetomidine—Vomiting—Doxorubicin—lung cancer	3.67e-05	0.000184	CcSEcCtD
Dexmedetomidine—Rash—Doxorubicin—lung cancer	3.64e-05	0.000182	CcSEcCtD
Dexmedetomidine—Dermatitis—Doxorubicin—lung cancer	3.64e-05	0.000182	CcSEcCtD
Dexmedetomidine—Headache—Doxorubicin—lung cancer	3.62e-05	0.000181	CcSEcCtD
Dexmedetomidine—Nausea—Doxorubicin—lung cancer	3.43e-05	0.000172	CcSEcCtD
Dexmedetomidine—ADRA2A—Signaling Pathways—KDR—lung cancer	5.55e-06	6.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CD—lung cancer	5.53e-06	6.54e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ABCB1—lung cancer	5.52e-06	6.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CXCL8—lung cancer	5.49e-06	6.5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAP2K1—lung cancer	5.48e-06	6.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—PIK3CA—lung cancer	5.48e-06	6.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—HRAS—lung cancer	5.46e-06	6.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CD—lung cancer	5.44e-06	6.44e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—TYMS—lung cancer	5.42e-06	6.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—KRAS—lung cancer	5.41e-06	6.41e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—PIK3CA—lung cancer	5.39e-06	6.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CD—lung cancer	5.37e-06	6.36e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTM1—lung cancer	5.36e-06	6.34e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—STK11—lung cancer	5.34e-06	6.32e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—POMC—lung cancer	5.34e-06	6.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—KRAS—lung cancer	5.33e-06	6.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PIK3CA—lung cancer	5.32e-06	6.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—AKT1—lung cancer	5.3e-06	6.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MDM2—lung cancer	5.3e-06	6.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ALB—lung cancer	5.3e-06	6.27e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CG—lung cancer	5.29e-06	6.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—RAF1—lung cancer	5.28e-06	6.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CASP3—lung cancer	5.26e-06	6.22e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL2—lung cancer	5.25e-06	6.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ERBB2—lung cancer	5.23e-06	6.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL6—lung cancer	5.22e-06	6.18e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CREBBP—lung cancer	5.2e-06	6.16e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CB—lung cancer	5.16e-06	6.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MTOR—lung cancer	5.16e-06	6.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCND1—lung cancer	5.12e-06	6.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APC—lung cancer	5.11e-06	6.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CG—lung cancer	5.11e-06	6.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KIT—lung cancer	5.11e-06	6.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—NRAS—lung cancer	5.11e-06	6.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—JUN—lung cancer	5.1e-06	6.04e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP1A1—lung cancer	5.08e-06	6.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGF—lung cancer	5.05e-06	5.98e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ERCC2—lung cancer	5.04e-06	5.97e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—POMC—lung cancer	5.03e-06	5.96e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	5.01e-06	5.93e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTEN—lung cancer	4.98e-06	5.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PIK3CA—lung cancer	4.97e-06	5.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MMP9—lung cancer	4.97e-06	5.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCL8—lung cancer	4.96e-06	5.87e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MDM2—lung cancer	4.95e-06	5.86e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1A—lung cancer	4.95e-06	5.86e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTP1—lung cancer	4.94e-06	5.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PTEN—lung cancer	4.94e-06	5.84e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—RAF1—lung cancer	4.94e-06	5.84e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CD—lung cancer	4.93e-06	5.84e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—HRAS—lung cancer	4.93e-06	5.83e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CREBBP—lung cancer	4.9e-06	5.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PIK3CA—lung cancer	4.89e-06	5.79e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—MAPK3—lung cancer	4.89e-06	5.79e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ERBB2—lung cancer	4.88e-06	5.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MDM2—lung cancer	4.87e-06	5.77e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ALB—lung cancer	4.87e-06	5.76e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—POMC—lung cancer	4.86e-06	5.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—RAF1—lung cancer	4.86e-06	5.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MTOR—lung cancer	4.82e-06	5.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CB—lung cancer	4.82e-06	5.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—AKT1—lung cancer	4.82e-06	5.7e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CAT—lung cancer	4.81e-06	5.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ERBB2—lung cancer	4.81e-06	5.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—BRAF—lung cancer	4.8e-06	5.68e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—AKT1—lung cancer	4.79e-06	5.67e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	4.78e-06	5.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—EP300—lung cancer	4.75e-06	5.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CASP3—lung cancer	4.74e-06	5.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6R—lung cancer	4.74e-06	5.61e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CB—lung cancer	4.74e-06	5.61e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MTOR—lung cancer	4.74e-06	5.61e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL2—lung cancer	4.74e-06	5.61e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CREBBP—lung cancer	4.74e-06	5.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL6—lung cancer	4.71e-06	5.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EP300—lung cancer	4.71e-06	5.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CB—lung cancer	4.68e-06	5.54e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ABCB1—lung cancer	4.68e-06	5.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—lung cancer	4.65e-06	5.51e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CD—lung cancer	4.65e-06	5.5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTGS2—lung cancer	4.64e-06	5.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCL8—lung cancer	4.63e-06	5.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCND1—lung cancer	4.62e-06	5.47e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—JUN—lung cancer	4.61e-06	5.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—HRAS—lung cancer	4.6e-06	5.44e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—TYMS—lung cancer	4.59e-06	5.44e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ALB—lung cancer	4.59e-06	5.43e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SRC—lung cancer	4.58e-06	5.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCL8—lung cancer	4.56e-06	5.39e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTM1—lung cancer	4.54e-06	5.37e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—HRAS—lung cancer	4.53e-06	5.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	4.52e-06	5.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	4.49e-06	5.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MMP9—lung cancer	4.48e-06	5.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—AKT1—lung cancer	4.47e-06	5.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1A—lung cancer	4.47e-06	5.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—lung cancer	4.46e-06	5.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTEN—lung cancer	4.46e-06	5.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	4.45e-06	5.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CASP3—lung cancer	4.43e-06	5.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL2—lung cancer	4.43e-06	5.24e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT3—lung cancer	4.42e-06	5.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NRAS—lung cancer	4.41e-06	5.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL6—lung cancer	4.4e-06	5.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—AKT1—lung cancer	4.4e-06	5.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—KRAS—lung cancer	4.4e-06	5.2e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CASP3—lung cancer	4.36e-06	5.16e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—APOA1—lung cancer	4.36e-06	5.16e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL2—lung cancer	4.36e-06	5.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—AKT1—lung cancer	4.35e-06	5.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL6—lung cancer	4.33e-06	5.13e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCND1—lung cancer	4.31e-06	5.11e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP1A1—lung cancer	4.31e-06	5.1e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—JUN—lung cancer	4.31e-06	5.09e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CB—lung cancer	4.3e-06	5.09e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ERCC2—lung cancer	4.27e-06	5.05e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTGS2—lung cancer	4.26e-06	5.04e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EP300—lung cancer	4.25e-06	5.03e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCND1—lung cancer	4.25e-06	5.02e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—JUN—lung cancer	4.24e-06	5.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK3—lung cancer	4.22e-06	4.99e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MMP9—lung cancer	4.19e-06	4.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1A—lung cancer	4.17e-06	4.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTEN—lung cancer	4.16e-06	4.93e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SRC—lung cancer	4.13e-06	4.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MMP9—lung cancer	4.12e-06	4.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1A—lung cancer	4.11e-06	4.86e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MYC—lung cancer	4.1e-06	4.86e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTEN—lung cancer	4.1e-06	4.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—AKT1—lung cancer	4.06e-06	4.81e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CB—lung cancer	4.05e-06	4.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTEN—lung cancer	4.04e-06	4.79e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	4.04e-06	4.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—lung cancer	4.03e-06	4.77e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MDM2—lung cancer	4.02e-06	4.76e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTGS2—lung cancer	4.02e-06	4.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—lung cancer	4.01e-06	4.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—RAF1—lung cancer	4.01e-06	4.74e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—AKT1—lung cancer	4e-06	4.73e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT3—lung cancer	3.99e-06	4.72e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CG—lung cancer	3.98e-06	4.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NRAS—lung cancer	3.98e-06	4.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EP300—lung cancer	3.97e-06	4.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ERBB2—lung cancer	3.97e-06	4.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MTOR—lung cancer	3.91e-06	4.63e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	3.91e-06	4.63e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EP300—lung cancer	3.91e-06	4.63e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SRC—lung cancer	3.86e-06	4.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—EP300—lung cancer	3.86e-06	4.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK3—lung cancer	3.81e-06	4.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SRC—lung cancer	3.8e-06	4.5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KRAS—lung cancer	3.79e-06	4.49e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—POMC—lung cancer	3.79e-06	4.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCL8—lung cancer	3.76e-06	4.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—lung cancer	3.76e-06	4.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—HRAS—lung cancer	3.74e-06	4.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT3—lung cancer	3.72e-06	4.41e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NRAS—lung cancer	3.72e-06	4.4e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTEN—lung cancer	3.71e-06	4.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MYC—lung cancer	3.7e-06	4.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—lung cancer	3.7e-06	4.38e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—APOA1—lung cancer	3.69e-06	4.37e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CREBBP—lung cancer	3.69e-06	4.37e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT3—lung cancer	3.67e-06	4.34e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NRAS—lung cancer	3.66e-06	4.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	3.63e-06	4.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—lung cancer	3.62e-06	4.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CASP3—lung cancer	3.6e-06	4.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL2—lung cancer	3.59e-06	4.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL6—lung cancer	3.58e-06	4.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK3—lung cancer	3.56e-06	4.21e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—EP300—lung cancer	3.54e-06	4.19e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.54e-06	4.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CA—lung cancer	3.51e-06	4.16e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCND1—lung cancer	3.5e-06	4.15e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTEN—lung cancer	3.5e-06	4.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK3—lung cancer	3.5e-06	4.14e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CD—lung cancer	3.5e-06	4.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—JUN—lung cancer	3.5e-06	4.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CA—lung cancer	3.48e-06	4.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MYC—lung cancer	3.46e-06	4.1e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ALB—lung cancer	3.45e-06	4.09e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KRAS—lung cancer	3.42e-06	4.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MYC—lung cancer	3.41e-06	4.03e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MMP9—lung cancer	3.4e-06	4.03e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	3.39e-06	4.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—lung cancer	3.38e-06	4.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTEN—lung cancer	3.38e-06	4e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CG—lung cancer	3.37e-06	3.99e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—lung cancer	3.37e-06	3.99e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—EP300—lung cancer	3.34e-06	3.95e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—lung cancer	3.33e-06	3.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—AKT1—lung cancer	3.3e-06	3.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EP300—lung cancer	3.23e-06	3.82e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HRAS—lung cancer	3.22e-06	3.81e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—POMC—lung cancer	3.21e-06	3.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KRAS—lung cancer	3.2e-06	3.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KRAS—lung cancer	3.15e-06	3.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	3.14e-06	3.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SRC—lung cancer	3.14e-06	3.71e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CREBBP—lung cancer	3.13e-06	3.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL6—lung cancer	3.08e-06	3.65e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—lung cancer	3.05e-06	3.62e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CB—lung cancer	3.05e-06	3.61e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—lung cancer	3.04e-06	3.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT3—lung cancer	3.02e-06	3.58e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS2—lung cancer	3.02e-06	3.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NRAS—lung cancer	3.02e-06	3.57e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CD—lung cancer	2.96e-06	3.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	2.94e-06	3.48e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ALB—lung cancer	2.93e-06	3.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HRAS—lung cancer	2.91e-06	3.44e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	2.89e-06	3.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK3—lung cancer	2.89e-06	3.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AKT1—lung cancer	2.87e-06	3.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CA—lung cancer	2.85e-06	3.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKT1—lung cancer	2.85e-06	3.37e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—lung cancer	2.84e-06	3.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MYC—lung cancer	2.81e-06	3.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—lung cancer	2.8e-06	3.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL6—lung cancer	2.78e-06	3.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—lung cancer	2.75e-06	3.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HRAS—lung cancer	2.72e-06	3.22e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HRAS—lung cancer	2.67e-06	3.17e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTEN—lung cancer	2.64e-06	3.12e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CA—lung cancer	2.62e-06	3.1e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL6—lung cancer	2.6e-06	3.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KRAS—lung cancer	2.6e-06	3.07e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CB—lung cancer	2.58e-06	3.06e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKT1—lung cancer	2.57e-06	3.04e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS2—lung cancer	2.56e-06	3.03e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL6—lung cancer	2.56e-06	3.03e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—EP300—lung cancer	2.51e-06	2.97e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CA—lung cancer	2.47e-06	2.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKT1—lung cancer	2.4e-06	2.84e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	2.39e-06	2.82e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKT1—lung cancer	2.36e-06	2.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AKT1—lung cancer	2.33e-06	2.76e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—lung cancer	2.31e-06	2.73e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTEN—lung cancer	2.23e-06	2.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HRAS—lung cancer	2.21e-06	2.61e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AKT1—lung cancer	2.14e-06	2.53e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—EP300—lung cancer	2.13e-06	2.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6—lung cancer	2.11e-06	2.5e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AKT1—lung cancer	2.02e-06	2.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKT1—lung cancer	1.95e-06	2.31e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CA—lung cancer	1.86e-06	2.2e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CA—lung cancer	1.58e-06	1.86e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AKT1—lung cancer	1.52e-06	1.8e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AKT1—lung cancer	1.29e-06	1.52e-05	CbGpPWpGaD
